Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose vitamin B3 for prevention of major adverse kidney events during septic shock
2024-517055-13-00Phase 3Completed
- Sponsor
- CHU Amiens-Picardie
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nicotinamide in septic shock and acute kidney failure (AKF) (2 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Major adverse kidney events at 30 days (MAKE30). Started Sep 2024; status: completed.
02
Drugs
nicotinamide
03
Conditions
septic shockacute kidney failure (AKF)
Beyond the preview
Go deeper on 2024-517055-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517055-13-00.